Skip to main content

Pathological Gambling

2
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Prevail Therapeutics
1 program
1
olanzapinePhase 31 trial
Active Trials
NCT00438776Completed42Est. Mar 2009
Emalex Biosciences
Emalex BiosciencesIL - Chicago
1 program
1
EcopipamPhase 21 trial
Active Trials
NCT01215357Completed34Est. Aug 2012
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Impulsivity in Pathological GamblingN/A1 trial
Active Trials
NCT00580567Completed120Est. Aug 2009
Abbott
AbbottABBOTT PARK, IL
1 program
fMRIN/A1 trial
Active Trials
NCT00211822Terminated57Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Prevail Therapeuticsolanzapine
Emalex BiosciencesEcopipam
Angeles TherapeuticsImpulsivity in Pathological Gambling
AbbottfMRI

Clinical Trials (4)

Total enrollment: 253 patients across 4 trials

NCT00438776Prevail Therapeuticsolanzapine

Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling

Start: Feb 2007Est. completion: Mar 200942 patients
Phase 3Completed
NCT01215357Emalex BiosciencesEcopipam

Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

Start: Oct 2010Est. completion: Aug 201234 patients
Phase 2Completed
NCT00580567Angeles TherapeuticsImpulsivity in Pathological Gambling

Impulsivity in Pathological Gambling

Start: Mar 2007Est. completion: Aug 2009120 patients
N/ACompleted
NCT00211822AbbottfMRI

Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)

Start: Nov 2004Est. completion: Dec 201057 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.